stockportfolio.pro
Stocks / ANAB vs PRCT
ANAB vs PRCT
AnaptysBio, Inc. and PROCEPT BioRobotics Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| AnaptysBio, Inc. (ANAB) | PROCEPT BioRobotics Corporation (PRCT) | |
|---|---|---|
| Market cap | $1.6B | $1.5B |
| Revenue (latest FY) | $234.60M | $308.05M |
| Net income (latest FY) | $-13.23M | $-95.57M |
| Revenue growth (5y CAGR) | 25.6% | 109.0% |
| Net margin | -5.6% | -31.0% |
| Return on equity | -35.6% | -26.1% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ANAB — free Open PRCT — freeFrequently asked questions
Which is bigger, ANAB or PRCT?
AnaptysBio, Inc. is larger by market capitalization — $1.6B versus $1.5B.
Which grows faster, ANAB or PRCT?
Over the last five fiscal years, PROCEPT BioRobotics Corporation grew revenue faster — 109.0%/yr versus 25.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.